+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tetanus - Pipeline Review, H1 2020

  • ID: 5017457
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 94 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • BioNet- Asia Co Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Panacea Biotec Ltd
  • MORE
Tetanus - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H1 2020, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Tetanus - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 5, 7, 2, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • BioNet- Asia Co Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Panacea Biotec Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Tetanus - Overview
  • Tetanus - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tetanus - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tetanus - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • BioNet- Asia Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Novo Medi Sciences Pvt Ltd
  • NTxBio LLC
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Seasons Healthcare Ltd
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Sichuan ZehaTimes Pharmaceutical Co Ltd
  • Stablepharma Ltd
  • Yisheng Biopharma Co Ltd
  • Yuxi Jiuzhou Biological Technology Co Ltd
  • Zhuhai Trinomab Biotechnology Co Ltd
  • Tetanus - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tetanus - Dormant Projects
  • Tetanus - Discontinued Products
  • Tetanus - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Tetanus, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Tetanus - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2020
  • Tetanus - Pipeline by Biken Co Ltd, H1 2020
  • Tetanus - Pipeline by Biological E Ltd, H1 2020
  • Tetanus - Pipeline by BioNet- Asia Co Ltd, H1 2020
  • Tetanus - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
  • Tetanus - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Tetanus - Pipeline by CanSino Biologics Inc, H1 2020
  • Tetanus - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
  • Tetanus - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Tetanus - Pipeline by GC Pharma, H1 2020
  • Tetanus - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Tetanus - Pipeline by KM Biologics Co Ltd, H1 2020
  • Tetanus - Pipeline by LG Chem Ltd, H1 2020
  • Tetanus - Pipeline by Novo Medi Sciences Pvt Ltd, H1 2020
  • Tetanus - Pipeline by NTxBio LLC, H1 2020
  • Tetanus - Pipeline by Olymvax Biopharmaceuticals Inc, H1 2020
  • Tetanus - Pipeline by Panacea Biotec Ltd, H1 2020
  • Tetanus - Pipeline by Sanofi Pasteur SA, H1 2020
  • Tetanus - Pipeline by Seasons Healthcare Ltd, H1 2020
  • Tetanus - Pipeline by Serum Institute of India Ltd, H1 2020
  • Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2020
  • Tetanus - Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, H1 2020
  • Tetanus - Pipeline by Stablepharma Ltd, H1 2020
  • Tetanus - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Tetanus - Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, H1 2020
  • Tetanus - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, H1 2020
  • Tetanus - Dormant Projects, H1 2020
  • Tetanus - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Tetanus - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Tetanus, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Beijing Minhai Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • BioNet- Asia Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Novo Medi Sciences Pvt Ltd
  • NTxBio LLC
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Seasons Healthcare Ltd
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Sichuan ZehaTimes Pharmaceutical Co Ltd
  • Stablepharma Ltd
  • Yisheng Biopharma Co Ltd
  • Yuxi Jiuzhou Biological Technology Co Ltd
  • Zhuhai Trinomab Biotechnology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll